openFDA
Cure8 regulatory brief
Ustekinumab-aekn FDA label update (2026-07-24)
Medications
Ustekinumab
Immunomodulators
IL-12/23 inhibitor
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Why This Matters
An updated FDA drug label affects how ustekinumab is prescribed and monitored. It confirms Crohn’s disease and ulcerative colitis as approved uses and highlights safety concerns (infections, TB screening, malignancy) that are directly relevant to patients on biologic therapy.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis being treated with or considering ustekinumab, caregivers, and clinicians who prescribe or monitor biologic therapies.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This is the official prescribing information for ustekinumab-aekn; it confirms the drug is indicated for adults with moderately to severely active Crohn’s disease and ulcerative colitis, as well as psoriasis and psoriatic arthritis.
The label emphasizes infection risks, the need to evaluate for tuberculosis before starting therapy, and cautions about malignancy risk and serious hypersensitivity reactions. It also advises against live vaccines during treatment and notes rare reports of noninfectious pneumonias and posterior reversible encephalopathy syndrome.
The label is a regulatory document intended for clinicians and includes detailed safety and monitoring instructions, not patient-specific medical advice. If you are taking or considering ustekinumab, discuss these risks and monitoring steps with your prescribing clinician.
Keep In Mind
This is the formal FDA prescribing information (regulatory record). It provides recommended screening and safety precautions for clinicians; it is not a patient-facing treatment guideline. Discuss individual risks, vaccination timing, and TB screening with your provider.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
PublisherU.S. Food and Drug Administration
SponsorTeva Pharmaceuticals USA, Inc.
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 24, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ustekinumab FDA label update (2026-06-19)
This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
DailyMed label update for STELARA
This label update affects people with Crohn’s disease or ulcerative colitis because it spells out approved uses, age ranges, and the official dosing schedules and safety warnings for ustekinumab (STELARA). Changes in the...